With a focus in the fast-growing world of next generation sequencing, Kailos Genetics, through its CLIA Services Laboratory, analyzes DNA for “genetic clues” associated with drug response, adverse response and diagnosis of disease. These clues enable physicians to proactively identify responders and non-responders to certain drug therapies, avoid serious adverse drug reactions that are genetically linked, and diagnose inherited and non-inherited diseases.
President & Chief Executive Officer
Chief Scientific Officer
Randy C. Bachmeyer
Chief Technology Officer
VP of Informatics and Chief Technology Officer
Chief Operations Officer
All resident associate companies on the HudsonAlpha campus are independently owned and operated.